As we reported in August, Irish drugmaker Elan is not yet ready to spin off its drug delivery unit. Turns out, the drug delivery unit, EDT, is broadening its manufacturing offerings. "While we have been 40 years manufacturing products for companies, it has almost exclusively been related to a drug delivery contract into which the parties have entered," spokeswoman Fidelma Callanan tells Outsourcing-pharma. "We want to extend this more to specialised manufacturing which is not necessarily tied to drug delivery contracts." Report
Note: This report was changed from an earlier version in which we said that Elan was moving away from drug delivery. Actually, it is the EDT unit that is broadening its focus. We apologize for the error.